Who
Matthew Winton
Chief Commercial and Business
Company insider
Files Form 4 as: Chief Commercial and Business, CervoMed; COO, Inozyme Pharma.
In numbers
- Trades disclosed
- 17
- Buys
- 3
- Sells
- 0
- Bought
- $117K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 3 Apr 2023
- Last trade
- 11 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Feb 2026filed 13 Feb 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 18 Nov 2025filed 19 Nov 2025 | CRVO CervoMedBiotechnology | SEC FORM 4 Bought | $12K1,500 at $7.95 | filing |
| 17 Nov 2025filed 19 Nov 2025 | CRVO CervoMedBiotechnology | SEC FORM 4 Bought | $30K3,500 at $8.43 | filing |
| 14 Nov 2025filed 17 Nov 2025 | CRVO CervoMedBiotechnology | SEC FORM 4 Bought | $76K10,000 at $7.57 | filing |
| 6 Oct 2025filed 8 Oct 2025 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code D | —41,500 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code D | —145,000 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharma | SEC FORM 4 Code U | $87K21,743 at $4.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Inozyme Pharma | SEC FORM 4 Code A | $11K14,355 at $0.74 | filing |
| 31 Mar 2025filed 2 Apr 2025 | Inozyme Pharma | SEC FORM 4 Code A | $1,9172,490 at $0.77 | filing |
| 11 Mar 2025filed 17 Mar 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
| 11 Mar 2025filed 17 Mar 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —41,500 at $0.00 | filing |
| 30 Sep 2024filed 3 Oct 2024 | Inozyme Pharma | SEC FORM 4 Code A | $7,6101,710 at $4.45 | filing |
| 28 Mar 2024filed 3 Apr 2024 | Inozyme Pharma | SEC FORM 4 Code A | $11K3,188 at $3.33 | filing |
| 13 Mar 2024filed 15 Mar 2024 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 3 Apr 2023filed 4 Apr 2023 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.